Biological age
No medical society currently recommends epigenetic clock testing
The absence is not an oversight. Guidelines require a demonstrated change in management, and that demonstration has not been made.
Patients arrive with methylation results and ask what to do about them. The honest answer is that no major medical body recommends the test, and the reasons are specific rather than dismissive.
The short version
- Guideline bodies require evidence that a test changes management and improves outcomes, not merely that it correlates with risk.
- Epigenetic clocks have the correlation. The management step has not been established.
- Reference datasets skew toward older adults of European descent, which limits confidence in other populations.
- A single timepoint captures methylation on one day, and the reliability data suggests that day matters more than expected.
What a guideline actually requires
For a test to enter routine practice, a body needs evidence on three points: that the test measures what it claims, that the result changes what a clinician would do, and that the change improves outcomes. Correlation with mortality satisfies the first and says nothing about the second or third.
This is the same bar that has kept many promising biomarkers in research use for decades. It is not scepticism about the biology. It is a demand for the intervening evidence.
The specific gaps
Different clocks give different estimates for the same person, and there is no consensus on which to use. Sample handling, laboratory method, and platform all affect the result. Most clocks were trained on samples from older adults of European descent, so performance in other groups is less certain.
Above all, nobody has established which interventions reliably lower an elevated reading. Without that, an abnormal result gives a clinician a number and no corresponding action.
What to do with a result you already have
Bring it, but bring it as context rather than as a finding. A clinician will reasonably redirect toward the measures that do drive management: blood pressure, lipids including apolipoprotein B where available, glycaemic control, smoking status, activity, and weight trajectory.
If a provider responds to your methylation result with a specific product recommendation, that recommendation is not coming from the evidence base.
Common questions
Will this change?
Plausibly. Trials using these measures as endpoints are underway. The reliability problem will need addressing first.
Is it worth paying for out of interest?
That is a personal decision. Just do not expect it to generate a clinical action, because currently it cannot.
Sources
- Biological age tests: what epigenetic clocks actually measure — https://ubiehealth.com/doctors-note/biological-age-testing-epigenetic-clock-guidance4262q2
- Epigenetic clocks: advancing towards meaningful clinical use — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12905613/